For Immediate Release

NEWTON, Mass./EWORLDWIRE/June 30, 2014.

NeuroHealing Pharmaceuticals Inc., a private clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the addition of Josh Hamermesh to the company’s Board of Directors. Josh Hamermesh has over 15 years of operating, start up, and consulting experience in the life sciences industry. He is currently a vice president at Locust Walk Partners, a transaction advisory firm that supports biopharmaceutical companies, working with clients to support their business development and financing initiatives. Previously, Hamermesh was vice president, Business & Corporate Development at Infinity Pharmaceuticals, where he was responsible for the company’s in-licensing, out-licensing and alliance management activities. Prior to Infinity, he held the position of senior vice president, Strategy & Corporate Development at Pervasis Therapeutics, where he led strategic partnering initiatives for the company’s product development portfolio. Hamermesh also served as vice president, Commercial & Business Development at Molecular Insight Pharmaceuticals, where he completed multiple in-licensing transactions and supported the company’s initial public offering. His biotech career began at Genzyme, where he served as chief operating officer of MG Biotherapeutics, a joint venture with Medtronic, after holding positions of increasing responsibility in marketing and business development. Prior to joining the life science industry, Hamermesh worked as a business strategy consultant at the Monitor Company. He holds a B.A., magna cum laude, from Amherst College and an M.B.A. from Harvard Business School. Hamermesh has completed Boston and New York marathons, coaches multiple youth sports teams, played professional basketball in the Israel national league, and has held leadership roles in local school and philanthropic organizations. “On behalf of the Board, I’m very pleased to welcome Josh Hamermesh as a new director of NeuroHealing. We believe that Josh’s business savvy, integrity and strategic planning in several biopharmaceutical companies at a similar stage as NeuroHealing will prove very valuable,” said Neal M. Farber, Ph.D., CEO of NeuroHealing. “We look forward to working with Josh and benefiting from his experience and judgment.” Mr. Hamermesh commented, “It’s an exciting time to join NeuroHealing’s Board of Directors, and I look forward to working with the team. With a continued focus on repositioning neurologically active compounds for important, specialty indications, the company is well positioned to deliver important new medicines to patients.” About NeuroHealing Pharmaceuticals Inc. ( NeuroHealing Pharmaceuticals Inc. is a clinical stage private company developing innovative treatments for specialty indications based on repositioning neurologically active compounds. Clinical stage programs include: – NH001 (phase II), a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative or minimally consciousness state. – NH004 (phase II), an anticholinergic agent in convenient thin film delivery to help treat Parkinsons and other patients with movement disorders suffering from sialorrhea (drooling) – NH02D, a neurologically active compound to treat premature ejaculation HTML: MOBILE: PDF: ONLINE NEWSROOM: LOGO:


KEYWORDS: drug research, biotech, biotechnology, NeuroHealing Pharmaceuticals Inc., Pharmaceuticals, neurology, board of directors, clinical trials SOURCE: NeuroHealing Pharmaceuticals Inc.

About the author